Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Income from Continuing Operations (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Income from Continuing Operations readings, the most recent being 11938000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 46.44% to 11938000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 71425000.0, a 33.16% increase, with the full-year FY2025 number at 81777000.0, up 30.69% from a year prior.
  • Income from Continuing Operations hit 11938000.0 in Q4 2025 for Enanta Pharmaceuticals, up from 18588000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 11938000.0 in Q4 2025 to a low of 81903000.0 in Q3 2021.
  • Median Income from Continuing Operations over the past 5 years was 29550500.0 (2021), compared with a mean of 30479650.0.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 503.91% in 2021 and later surged 67.3% in 2022.
  • Enanta Pharmaceuticals' Income from Continuing Operations stood at 30115000.0 in 2021, then increased by 3.75% to 28986000.0 in 2022, then dropped by 15.25% to 33407000.0 in 2023, then skyrocketed by 33.28% to 22290000.0 in 2024, then skyrocketed by 46.44% to 11938000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 11938000.0 (Q4 2025), 18588000.0 (Q3 2025), and 18255000.0 (Q2 2025) per Business Quant data.